A Changing Landscape of Advanced Prostate Cancer: Understanding Mechanisms of Resistance to Potent Hormonal Therapies

Abstract

Transition to a neuroendocrine prostate cancer (NEPC) phenotype has emerged as an important mechanism of treatment resistance to androgen receptor (AR) therapies for patients with metastatic prostate cancer. During the course of this Award, I have performed extensive, first in-field molecular characterization of metastatic tumor biopsies from 81 patients with castration resistant adenocarcinoma and neuroendocrine prostate cancer (Beltran et al, Nature Medicine, in press). Whole exome, transcriptome, and CpG DNA methylation integrative analyses point to key drivers of NEPC including loss of RB1 and TP53 and primarily epigenetic changes.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2015
Accession Number
AD1007413

Entities

People

  • Himisha Beltran

Organizations

  • Weill Cornell Medicine

Tags

DTIC Thesaurus Topics

  • Androgen Receptors
  • Biology
  • Biomedical Research
  • Blood
  • Blood Cells
  • Breast Cancer
  • Cancer
  • Carcinoma
  • Cell Physiological Processes
  • Detection
  • Diseases And Disorders
  • Gene Expression
  • Medical Personnel
  • Neoplasms
  • Oncology
  • Prostate Cancer
  • Tissues

Fields of Study

  • Biology

Readers

  • Molecular and genetic basis of cancer.
  • Prostate Cancer Biology.